SORAFENIB V LEChENII RASPROSTRANENNOGO GEPATOTsELLYuLYaRNOGO RAKA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of a prospective study on effectiveness of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) in ROSC named after N.N. Blokhin and other oncological centers in Russia for the period from February 2009 to August 2012. The study included 130 patients treated with peroral sorafenib in an initial dose of 400 mg 2 times a day daily. The study confirmed the international evidence on the efficacy and safety of sorafenib in patients with advanced HCC with satisfactory liver function (Child Pugh class A). It is emphasized that a careful dynamic assessment of functional status of the liver, appropriate and timely treatment of pre-existing liver diseases and toxicity of sorafenib are the basis for an effective anti-tumor treatment of HCC.

Full Text

Restricted Access

References

  1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3): 581-92.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Т. 20. № 3 (прил. 1).
  3. Bruix J., Barrera J.M., Calvet X., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-6.
  4. Shiratori Y., Shiina S., Imamura M., et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027- 33.
  5. Forner A., Reig M.E., de Lope C.R., Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
  6. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-99.
  7. Palmer D.H., Hussain S.A., Johnson P.J. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13: 1555-68.
  8. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
  9. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10: 25-34.
  10. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
  11. Ozenne V., Paradis V., Pernot S., et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106-10.
  12. Worns M.A., Weinmann A., Pfingst K., et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-95.
  13. Sobin L., Wittekind C., ed. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002
  14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
  15. Ioannou G., Splan M., Weiss N., et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-45.
  16. Bartlett D.L., DiBisceglie A.M., Dawson L.A. Cancer of the liver. In: DeVita V.T., Lawrence T.S., Rosenberg S.A., eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: 997-1018.
  17. Lok A.S., McMahon B.J. Chronic Hepatitis B: update 2009. Hepatology 2009; 50(3): 661-62.
  18. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009: 49(4): 1335-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies